What happened in China

China's biotech sector has completed a structural shift. Once characterised as the industry's back-office — reliable for molecule synthesis and contract research — it is now the source of headline licensing deals that are reshaping global pharma deal flow.

Fully one-third of the industry's licensing spending in 2025 involved drugs originating from China, according to analyst data cited by BioPharma Dive. Licensing agreements involving Chinese drug candidates were already on a record pace in 2025, and Reuters reported in February 2026 that the boom was projected to hit a new record as China's pipeline continued to swell.

The numbers are not abstract. Pfizer licensed a bispecific antibody from Chinese company 3SBio with $1.25 billion upfront in 2025. AstraZeneca inked a $5.3 billion AI-enabled small molecule deal with a Chinese partner that same year, signed an agreement with Beijing-based Jacobio Pharma for exclusive development and commercialisation rights to a drug candidate, and then committed to the largest single deal driving the 2026 record: an experimental weight-loss drug partnership with CSPC Pharmaceutical Group worth up to $18.5 billion.

How it works / the detail

The structural advantages are durable, not cyclical. China's innovation engine rests on four regional clusters — Beijing's Zhongguancun Life Science Park, Shanghai's Zhangjiang Pharma Valley, Shenzhen, and Guangzhou/Suzhou — supported by pro-biotech policy, broad patient availability, and rapid trial execution.

On clinical trials specifically, China has surpassed Europe in volume, according to a Nature article tracking its growing global competitiveness. Enrollment in Asia tends to be faster than in Europe, where recruitment delays are a persistent problem in oncology and cell and gene therapy studies. Direct trial execution costs in China are lower than in both the US and EU.

The result: Chinese biotechs can move a molecule from candidate to licensable asset faster and at lower cost than most European peers — and they are showcasing those assets directly to Big Pharma. The 2026 China FIC Innovation and Collaboration Summit, held in San Francisco, saw Chinese pharmaceutical companies presenting their innovative pipelines to the same audience European founders are pitching.

European comparison / the gap

Europe's clinical trial infrastructure is slower and more expensive. Recruitment delays are not an edge case — they are a structural feature, particularly in the therapeutic areas where Chinese biotechs are most active. Chinese biotechs have moved from back-office service providers to direct competitors for the same licensing cheques from the same Big Pharma business development teams.

For European founders, that means two pressures converging simultaneously. First, the assets they are building are being benchmarked against Chinese candidates that were generated more cheaply and validated more quickly. Second, the licensing market that European biotechs depend on is increasingly shaped by deal structures and valuations set by Chinese transactions — transactions that can reach into the tens of billions.

What European founders/investors should do

Three adjustments are worth making now.

Audit your competitive set honestly. If your asset is in oncology, metabolic disease, or any area where Chinese biotechs are active, they are in your competitive landscape — not just Western peers. Know what is coming out of Zhangjiang and Zhongguancun.

Treat trial execution speed as a commercial variable. A slower European clinical programme is not just a cost issue — it is a valuation issue. The bar for what a credible clinical programme looks like is being reset by Chinese execution timelines. Investors will start asking why your Phase II takes twice as long.

Look at China for partnership, not just competition. Chinese biotechs are expanding globally through out-licensing and are actively reshaping deal structures. European founders with platform technologies or regulatory expertise in EU markets have something Chinese partners need. The deal flow is not one-directional.

Closing line

China's biotech sector spent a decade building the capabilities that Big Pharma is now paying record sums to access — European founders have less time than they think to decide whether China is their competition, their benchmark, or their next partner.

Sources

Sources

Sources

Sources

Sources

Sources

Sources

Sources

Sources

Sources

Sources

Sources

Sources

Sources